323 related articles for article (PubMed ID: 23352841)
41. A comparative study of ERG status assessment on DNA, mRNA, and protein levels using unique samples from a Swedish biopsy cohort.
Svensson MA; Perner S; Ohlson AL; Day JR; Groskopf J; Kirsten R; Sollie T; Helenius G; Andersson SO; Demichelis F; Andrén O; Rubin MA
Appl Immunohistochem Mol Morphol; 2014; 22(2):136-41. PubMed ID: 24517914
[TBL] [Abstract][Full Text] [Related]
42. Nucleotide resolution analysis of TMPRSS2 and ERG rearrangements in prostate cancer.
Weier C; Haffner MC; Mosbruger T; Esopi DM; Hicks J; Zheng Q; Fedor H; Isaacs WB; De Marzo AM; Nelson WG; Yegnasubramanian S
J Pathol; 2013 Jun; 230(2):174-83. PubMed ID: 23447416
[TBL] [Abstract][Full Text] [Related]
43. TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer.
Swanson TA; Krueger SA; Galoforo S; Thibodeau BJ; Martinez AA; Wilson GD; Marples B
Prostate; 2011 Oct; 71(14):1548-58. PubMed ID: 21394739
[TBL] [Abstract][Full Text] [Related]
44. Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer.
Zeng W; Sun H; Meng F; Liu Z; Xiong J; Zhou S; Li F; Hu J; Hu Z; Liu Z
Int J Clin Exp Pathol; 2015; 8(2):1878-88. PubMed ID: 25973080
[TBL] [Abstract][Full Text] [Related]
45. [TMPRSS2-ERG gene fusion in metastatic prostate cancers: a study of fine needle aspiration specimens].
Xiao L; Zhu XZ; Wang Y; Gong Y; Guo CC
Zhonghua Bing Li Xue Za Zhi; 2011 Jun; 40(6):392-6. PubMed ID: 21914348
[TBL] [Abstract][Full Text] [Related]
46. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate.
Danila DC; Anand A; Sung CC; Heller G; Leversha MA; Cao L; Lilja H; Molina A; Sawyers CL; Fleisher M; Scher HI
Eur Urol; 2011 Nov; 60(5):897-904. PubMed ID: 21802835
[TBL] [Abstract][Full Text] [Related]
47. ERG rearrangement is present in a subset of transition zone prostatic tumors.
Falzarano SM; Navas M; Simmerman K; Klein EA; Rubin MA; Zhou M; Magi-Galluzzi C
Mod Pathol; 2010 Nov; 23(11):1499-506. PubMed ID: 20693982
[TBL] [Abstract][Full Text] [Related]
48. TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarcinoma.
Albadine R; Latour M; Toubaji A; Haffner M; Isaacs WB; A Platz E; Meeker AK; Demarzo AM; Epstein JI; Netto GJ
Mod Pathol; 2009 Nov; 22(11):1415-22. PubMed ID: 19734849
[TBL] [Abstract][Full Text] [Related]
49. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O
Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440
[TBL] [Abstract][Full Text] [Related]
50. Improved method of detecting the ERG gene rearrangement in prostate cancer using combined dual-color chromogenic and silver in situ hybridization.
Braun M; Stomper J; Boehm D; Vogel W; Scheble VJ; Wernert N; Adler D; Fend F; Kristiansen G; Perner S
J Mol Diagn; 2012 Jul; 14(4):322-7. PubMed ID: 22642898
[TBL] [Abstract][Full Text] [Related]
51. Detection of TMPRSS2-ETS fusions by a multiprobe fluorescence in situ hybridization assay for the early diagnosis of prostate cancer: a pilot study.
Sun QP; Li LY; Chen Z; Pang J; Yang WJ; Zhou XF; Qiu JG; Su ZL; He D; Gao X
J Mol Diagn; 2010 Sep; 12(5):718-24. PubMed ID: 20616363
[TBL] [Abstract][Full Text] [Related]
52. TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications.
Barry M; Perner S; Demichelis F; Rubin MA
Urology; 2007 Oct; 70(4):630-3. PubMed ID: 17991527
[TBL] [Abstract][Full Text] [Related]
53. Prevalence and clinical application of
Kong DP; Chen R; Zhang CL; Zhang W; Xiao GA; Wang FB; Ta N; Gao X; Sun YH
Asian J Androl; 2020; 22(2):200-207. PubMed ID: 31210145
[TBL] [Abstract][Full Text] [Related]
54. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers.
Rajput AB; Miller MA; De Luca A; Boyd N; Leung S; Hurtado-Coll A; Fazli L; Jones EC; Palmer JB; Gleave ME; Cox ME; Huntsman DG
J Clin Pathol; 2007 Nov; 60(11):1238-43. PubMed ID: 17259299
[TBL] [Abstract][Full Text] [Related]
55. Relevance of cohort design for studying the frequency of the ERG rearrangement in prostate cancer.
Braun M; Scheble VJ; Menon R; Scharf G; Wilbertz T; Petersen K; Beschorner C; Reischl M; Kuefer R; Schilling D; Stenzl A; Kristiansen G; Rubin MA; Fend F; Perner S
Histopathology; 2011 Jun; 58(7):1028-36. PubMed ID: 21707704
[TBL] [Abstract][Full Text] [Related]
56. Delineation of TMPRSS2-ERG splice variants in prostate cancer.
Hu Y; Dobi A; Sreenath T; Cook C; Tadase AY; Ravindranath L; Cullen J; Furusato B; Chen Y; Thangapazham RL; Mohamed A; Sun C; Sesterhenn IA; McLeod DG; Petrovics G; Srivastava S
Clin Cancer Res; 2008 Aug; 14(15):4719-25. PubMed ID: 18676740
[TBL] [Abstract][Full Text] [Related]
57. A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis.
Lapointe J; Kim YH; Miller MA; Li C; Kaygusuz G; van de Rijn M; Huntsman DG; Brooks JD; Pollack JR
Mod Pathol; 2007 Apr; 20(4):467-73. PubMed ID: 17334351
[TBL] [Abstract][Full Text] [Related]
58. Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3-ERG gene rearrangement and an unfavorable clinical course.
Perner S; Rupp NJ; Braun M; Rubin MA; Moch H; Dietel M; Wernert N; Jung K; Stephan C; Kristiansen G
Int J Cancer; 2013 Feb; 132(4):807-12. PubMed ID: 22821757
[TBL] [Abstract][Full Text] [Related]
59. TMPRSS2:ERG fusion gene occurs less frequently in Chinese patients with prostate cancer.
Jiang H; Mao X; Huang X; Zhao J; Wang L; Xu J; Zhang H; Lu Y; Yu Y
Tumour Biol; 2016 Sep; 37(9):12397-12402. PubMed ID: 27320318
[TBL] [Abstract][Full Text] [Related]
60. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer.
Mehra R; Tomlins SA; Shen R; Nadeem O; Wang L; Wei JT; Pienta KJ; Ghosh D; Rubin MA; Chinnaiyan AM; Shah RB
Mod Pathol; 2007 May; 20(5):538-44. PubMed ID: 17334343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]